Pyoderma gangrenosum
Pyoderma gangrenosum ເປັນພະຍາດຜິວໜັງອັກເສບທີ່ຫາຍາກ ເຊິ່ງມີຕຸ່ມໜອງຫຼືຕຸ່ມທີ່ເຈັບປວດ ກາຍເປັນບາດແຜທີ່ຈະເລີນເຕີບຂຶ້ນແບບແບບໜ້ອຍ. Pyoderma gangrenosum ບໍ່ຕິດເຊື້ອ. ການປິ່ນປົວອາດຈະປະກອບດ້ວຍcorticosteroids, ciclosporin ຫຼືຢາຕ້ານທານmonoclonal ຕ່າງໆ. ແມ່ນວ່າມັນສາມາດເຮັດໃຫ້ມີຜົນກະທົບຕໍ່ຄົນໃນທຸກແວດ, ຜົນກະທົບສ່ວນໃຫຍ່ມັກເກີດຂຶ້ນໃນຜູ້ອາຍຸ40‑50 ປີ.
☆ AI Dermatology — Free Service
ໃນປີ 2022 Stiftung Warentest ຜົນໄດ້ຮັບຈາກເຢຍລະມັນ, ຄວາມພໍໃຈຂອງຜູ້ບໍລິໂພກກັບ ModelDerm ແມ່ນຕໍ່າກວ່າການປຶກສາຫາລືທາງດ້ານການປິ່ນປົວທາງໂທລະສັບເລັກນ້ອຍເທົ່ານັ້ນ.
ໃນປີ 2022 Stiftung Warentest ຜົນໄດ້ຮັບຈາກເຢຍລະມັນ, ຄວາມພໍໃຈຂອງຜູ້ບໍລິໂພກກັບ ModelDerm ແມ່ນຕໍ່າກວ່າການປຶກສາຫາລືທາງດ້ານການປິ່ນປົວທາງໂທລະສັບເລັກນ້ອຍເທົ່ານັ້ນ.
ບາດແຜຖະຫຼອກຂອງບາງຄົນແມ່ນຕາມຕົນເອງ.
relevance score : -100.0%
ReferencesPyoderma gangrenosum ເປັນສະພາບຜິວໜັງທີ່ຍາກທີ່ເຮັດໃຫ້ເກີດແຜ່ທີ່ມີຂອບສີແດງ ຫຼື ສີມ່ວງ. ມັນຖືກຈັດໝວດເປັນພະຍາດອັກເສບ ແລະເປັນສ່ວນຫນຶ່ງຂອງກຸ່ມທີ່ເອີ້ນວ່າ neutrophilic dermatoses. ສາເຫດຂອງ pyoderma gangrenosum ມີຄວາມຊັບຊ້ອນ ແລະກ່ຽວຂ້ອງກັບບັນຫາທີ່ມີພູມຕ້ານທານ ຈາກກໍາເນີດ ແລະການປັບຕົວໃນຄົນທີ່ມີເຊື້ອພັນທຸກໍາ. ບໍ່ດັ່ງນັ້ນ, ນັກຄົ້ນຄວາມສາມາດສຸມໃສ່ການຮາກຜົມເປັນຈຸດເລີ່ມຕົ້ນຂອງພະຍາດ.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum ເປັນສະພາບຜິວໜັງທີ່ຫາຍາກເຮັດໃຫ້ເກີດບາດແຜທີ່ເຈັບປວດທີ່ສຸດ. ໃນຂະນະທີ່ພວກເຮົາບໍ່ເຂົ້າໃຈຢ່າງຄົບຖ້ວນກ່ຽວກັບສາເຫດຂອງມັນ, ພວກເຮົາຮູ້ວ່າມັນກ່ຽວຂ້ອງກັບກິດຈະການທີ່ເພີ່ມຂຶ້ນຂອງຈຸລັງພູມຕ້ານທານບາງຢ່າງ. ການປິ່ນປົວພະຍາດແມ່ນບໍ່ງ່າຍດາຍ. ພວກເຮົາມີຢາຕ່າງໆທີ່ສະກັດກັ້ນລະບົບພູມຕ້ານທານຫຼືດັດແປງກິດຈະການຂອງມັນ. ພ້ອມກັບນັ້ນ, ພວກເຮົາຍັງສຸມໃສ່ການປິ່ນປົວບາດແຜແລະການຄຸ້ມຄອງອາການເຈັບປວດ. Corticosteroids ແລະ cyclosporine ມັກຈະເປັນທາງເລືອກທຳອິດສໍາລັບການປິ່ນປົວ, ແຕ່ບໍ່ດົນມານີ້ມີການຄົ້ນຄວ້າເພີ່ມເຕີມກ່ຽວກັບການນໍາໃຊ້ຊີວະພາບທີ່ເຊັ່ນTNF-α inhibitors. ຊີວະວິທະຍາເຫຼົ່ານີ້ແມ່ນການປະເມີນທີ່ນິຍົມຂຶ້ນ, ໂດຍສະເພາະໃນຄົນເຈັບທີ່ມີສະພາບອັກເສບອື່ນໆ, ແລະພວກມັນຖືກນໍາໃຊ້ໃນຂະບວນການຂອງພະຍາດກ່ອນຫນ້ານີ້.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
